Several studies have demonstrated the inhibition of CXCL8 expression by PI3K inhibitors in vitro; LY294002 [94,96] and wortmanin [94] can effectively down-regulate TNFα-induced CXCL8 expression in liver cells, while other agents including GDC-0941, BEZ-235 and SHBM1009 down-regulate EGF-stimulated CXCL8 expression in NSCLC cells [97]. This evidence concerns the gene CXCL8 and non-small cell lung carcinoma.